Ranbaxy gets U.S. FDA approval for Cefadroxil powder
Facebook Twitter google+ RSS Feed

Ranbaxy gets U.S. FDA approval for Cefadroxil powder

Friday, 28 March 2003, 08:00 Hrs
Printer Print Email Email
NEW DELHI: India's pharma major Ranbaxy Laboratories Ltd (RLL) has received approval from the U.S. Food and Drug Administration (FDA) to market its antibiotic Cefadroxil Powder for Oral Suspension USP, the company said.

The approval for oral suspension in 125 mg/5 ml, 250 mg/5 ml and 500 mg/5 ml strengths will see the antibiotic being marketed in the U.S. from June, the company said in a statement Thursday.

Patients who are allergic to either penicillin or cephalosporin antibiotics in any form would have to consult their doctor before taking Cefadroxil.

In 2002, the total sales of Cefadroxil totaled $37.7 million, while sales of the suspensions were $16.7 million, said Ranbaxy.
Source: IANS
Experts on SiliconIndia
Santhosh  K
Sr. Soft. Engg.
Oracle India
Nehal Vyas
Sr. Team Lead
Cyberoam Tech.
Rani Malli
Sr. Director
Philips
Sr. Executive
ISB
Vijay Balkrishna Konduskar
Business Consultant
Imans Web Tech
Dr L P  Sharma
Technical Director
NIC
Reena Khanna
Founder
Solitaireworld
Dellas  Asse
sys-network admin
Computer Station
Write your comment now
Submit Reset
SPOTLIGHT